Netarsudil
- Generic Name
- Netarsudil
- Brand Names
- Rhopressa, Rocklatan, Rhokiinsa
- Drug Type
- Small Molecule
- Chemical Formula
- C28H27N3O3
- CAS Number
- 1254032-66-0
- Unique Ingredient Identifier
- W6I5QDT7QI
- Background
A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous
As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.
- Indication
Netarsudil is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension .
- Associated Conditions
- Increased Intra Ocular Pressure (IOP)
Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty
- Conditions
- Fuchs' Endothelial Dystrophy
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Massachusetts Eye and Ear Infirmary
- Target Recruit Count
- 25
- Registration Number
- NCT04752020
- Locations
- 🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 245
- Registration Number
- NCT04620135
- Locations
- 🇯🇵
Seijo Clinic, Setagaya-Ku, Tokyo, Japan
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04498169
- Locations
- 🇺🇸
Orange County Ophthalmology, Garden Grove, California, United States
🇺🇸Comprehensive Eye Care, Westerville, Ohio, United States
🇺🇸Cincinnati Eye Institute, Edgewood, Kentucky, United States
Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
- Conditions
- Ocular HypertensionSuspect Glaucoma
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 10
- Registration Number
- NCT04401982
- Locations
- 🇺🇸
Maryland Eye Consultants and Surgeons, Silver Spring, Maryland, United States
🇺🇸UM Faculty Physicians, Inc. | 5900 Waterloo Crossing, Columbia, Maryland, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- University of the Incarnate Word
- Target Recruit Count
- 10
- Registration Number
- NCT04234932
- Locations
- 🇺🇸
University of the Incarnate Word, San Antonio, Texas, United States
Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
- Conditions
- Fuchs' Endothelial DystrophyCataract
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Massachusetts Eye and Ear Infirmary
- Target Recruit Count
- 10
- Registration Number
- NCT04057053
- Locations
- 🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
- Conditions
- Fuchs Endothelial Dystrophy
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Price Vision Group
- Target Recruit Count
- 29
- Registration Number
- NCT04051463
- Locations
- 🇺🇸
Price Vision Group, Indianapolis, Indiana, United States
Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Price Vision Group
- Target Recruit Count
- 19
- Registration Number
- NCT03971357
- Locations
- 🇺🇸
Price Vision Group, Indianapolis, Indiana, United States
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- Other: Netarsudil Ophthalmic Solution Placebo
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 215
- Registration Number
- NCT03844945
- Locations
- 🇯🇵
Yoshimura Eye & Internal Medical Clinic, Mishima, Shiizuoka, Japan
🇯🇵Tamagawa Eye Clinic, Ota-ku, Tokyo, Japan
🇯🇵Yubikai Kawaguchi Aozora Eye Clinic, Kawaguchi-shi, Saitama-Ken, Japan
Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 261
- Registration Number
- NCT03808688
- Locations
- 🇺🇸
Keystone Research, Austin, Texas, United States
🇺🇸The Eye Centers of Racine and Kenosha, Racine, Wisconsin, United States
🇺🇸Coastal Research Associates, LLC, Roswell, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.